PRO 045

Drug Profile

PRO 045

Alternative Names: BMN-045; PRO045

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Prosensa
  • Developer BioMarin Nederland
  • Class Antisense oligonucleotides
  • Mechanism of Action Antisense RNA modulators; Dystrophin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 31 May 2016 Discontinued - Phase-II for Duchenne muscular dystrophy (In adolescents, In children) in Netherlands, United Kingdom, Italy, France, Belgium (SC)
  • 28 Apr 2015 Prosensa Therapeutics is now called BioMarin Nederland
  • 30 Mar 2015 Phase-II clinical trials in Duchenne muscular dystrophy (In adolescents, In children) in Belgium, France, Italy, United Kingdom and Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top